Petra Baji1, László Gulácsi1, Valentin Brodszky1, Zsuzsanna Végh2, Silvio Danese3, Peter M Irving4, Laurent Peyrin-Biroulet5, Stefan Schreiber6, Fanni Rencz1,7, Péter L Lakatos2, Márta Péntek1. 1. Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary. 2. 1st Department of Medicine, Semmelweis University, Budapest, Hungary. 3. Department of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy. 4. IBD Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK. 5. Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France. 6. Department Internal Medicine I, Kiel University, University Hospital, Kiel, Germany. 7. Semmelweis University Doctoral School of Clinical Medicine, Budapest, Hungary.
Abstract
BACKGROUND: In clinical practice, treatment sequences of biologicals are applied for active fistulising Crohn's disease, however underlying health economic analyses are lacking. OBJECTIVE: The purpose of this study was to analyse the cost-effectiveness of different biological sequences including infliximab, biosimilar-infliximab, adalimumab and vedolizumab in nine European countries. METHODS: A Markov model was developed to compare treatment sequences of one, two and three biologicals from the payer's perspective on a five-year time horizon. Data on effectiveness and health state utilities were obtained from the literature. Country-specific costs were considered. Calculations were performed with both official list prices and estimated real prices of biologicals. RESULTS: Biosimilar-infliximab is the most cost-effective treatment against standard care across the countries (with list prices: €34684-€72551/quality adjusted life year; with estimated real prices: €24364-€56086/quality adjusted life year). The most cost-effective two-agent sequence, except for Germany, is the biosimilar-infliximab-adalimumab therapy compared with single biosimilar-infliximab (with list prices: €58533-€133831/quality adjusted life year; with estimated prices: €45513-€105875/quality adjusted life year). The cost-effectiveness of the biosimilar-infliximab-adalimumab-vedolizumab three-agent sequence compared wit biosimilar-infliximab -adalimumab is €87214-€152901/quality adjusted life year. CONCLUSIONS: The suggested first-choice biological treatment is biosimilar-infliximab. In case of treatment failure, switching to adalimumab then to vedolizumab provides meaningful additional health gains but at increased costs. Inter-country differences in cost-effectiveness are remarkable due to significant differences in costs.
BACKGROUND: In clinical practice, treatment sequences of biologicals are applied for active fistulising Crohn's disease, however underlying health economic analyses are lacking. OBJECTIVE: The purpose of this study was to analyse the cost-effectiveness of different biological sequences including infliximab, biosimilar-infliximab, adalimumab and vedolizumab in nine European countries. METHODS: A Markov model was developed to compare treatment sequences of one, two and three biologicals from the payer's perspective on a five-year time horizon. Data on effectiveness and health state utilities were obtained from the literature. Country-specific costs were considered. Calculations were performed with both official list prices and estimated real prices of biologicals. RESULTS: Biosimilar-infliximab is the most cost-effective treatment against standard care across the countries (with list prices: €34684-€72551/quality adjusted life year; with estimated real prices: €24364-€56086/quality adjusted life year). The most cost-effective two-agent sequence, except for Germany, is the biosimilar-infliximab-adalimumab therapy compared with single biosimilar-infliximab (with list prices: €58533-€133831/quality adjusted life year; with estimated prices: €45513-€105875/quality adjusted life year). The cost-effectiveness of the biosimilar-infliximab-adalimumab-vedolizumab three-agent sequence compared wit biosimilar-infliximab -adalimumab is €87214-€152901/quality adjusted life year. CONCLUSIONS: The suggested first-choice biological treatment is biosimilar-infliximab. In case of treatment failure, switching to adalimumab then to vedolizumab provides meaningful additional health gains but at increased costs. Inter-country differences in cost-effectiveness are remarkable due to significant differences in costs.
Authors: László Gulácsi; Fanni Rencz; Gyula Poór; Zoltán Szekanecz; Valentin Brodszky; Petra Baji; Márta Péntek Journal: Ann Rheum Dis Date: 2016-02-17 Impact factor: 19.103
Authors: Valentin Brodszky; Fanni Rencz; Márta Péntek; Petra Baji; Péter L Lakatos; László Gulácsi Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2015-07-10 Impact factor: 2.217
Authors: Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682
Authors: J-F Colombel; D A Schwartz; W J Sandborn; M A Kamm; G D'Haens; P Rutgeerts; R Enns; R Panaccione; S Schreiber; J Li; J D Kent; K G Lomax; P F Pollack Journal: Gut Date: 2009-02-06 Impact factor: 23.059
Authors: Fanni Rencz; Peter L Lakatos; László Gulácsi; Valentin Brodszky; Zsuzsanna Kürti; Szilvia Lovas; János Banai; László Herszényi; Tamás Cserni; Tamás Molnár; Márta Péntek; Károly Palatka Journal: Qual Life Res Date: 2018-09-17 Impact factor: 4.147
Authors: Frank I Scott; Michelle Luo; Yash Shah; Karen Lasch; Ravy K Vajravelu; Ronac Mamtani; Blair Fennimore; Mark E Gerich; James D Lewis Journal: J Crohns Colitis Date: 2020-06-19 Impact factor: 9.071
Authors: Kapil Sahnan; Phil J Tozer; Samuel O Adegbola; Matthew J Lee; Nick Heywood; Angus G K McNair; Daniel Hind; Nuha Yassin; Alan J Lobo; Steven R Brown; Shaji Sebastian; Robin K S Phillips; Phillip F C Lung; Omar D Faiz; Kay Crook; Sue Blackwell; Azmina Verjee; Ailsa L Hart; Nicola S Fearnhead Journal: Gut Date: 2018-02-03 Impact factor: 23.059